Investigational drugs for retinal vein occlusion

References

• Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion-consensus document. Ophthalmologica. 2011;226:4–28.
   PubMed Web of Science ®Google Scholar
• McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113–1123.e15.
   Google Scholar
• Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The blue mountains eye study. Arch Ophthalmol. 1996;114(10):1243–1247.
   PubMed Web of Science ®Google Scholar
• Rogers S, McIntosh RL, Cheung N, et al.; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313–319.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc. 2000;98:133–141.
   PubMedGoogle Scholar
• Pulido JS, Flaxel CJ, Adelman RA, et al. Retinal vein occlusions preferred practice pattern(®) guidelines. Ophthalmology. 2016;123(1):P182–P208.
   Google Scholar
• Fekrat S, Shea AM, Hammill BG, et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin. 2010;26(1):223–230.
   PubMed Web of Science ®Google Scholar
• Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007;114(3):520–524.
   PubMed Web of Science ®Google Scholar
• Risk factors for branch retinal vein occlusion. The eye disease case-control study group. Am J Ophthalmol. 1993 15;116:286–296.
   PubMed Web of Science ®Google Scholar
• Risk factors for central retinal vein occlusion. The eye disease case-control study group. Arch Ophthalmol. 1996;114:545–554.
   PubMed Web of Science ®Google Scholar
• Jaulim A, Ahmed B, Khanam T, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, andcomplications. An update of the literature. Retina. 2013;33:901–910.
   PubMed Web of Science ®Google Scholar
• Hirota A, Mishima HK, Kiuchi Y. Incidence of retinal vein occlusion at the Glaucoma Clinic of Hiroshima University. Ophthalmologica. 1997;211:288–291.
   PubMed Web of Science ®Google Scholar
• Dominguez E, Raoul W, Calippe B, et al. Experimental branch retinal vein occlusion induces upstream pericyte loss and vascular destabilization. PLoS One. 2015 24;10(7):e0132644.
   Web of Science ®Google Scholar
• Sarao V, Bertoli F, Veritti D, et al. Pharmacotherapy for treatment of retinal vein occlusion. Expert Opin Pharmacother. 2014;15:2373–2384.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophthalmologica. 2009;223:298–305.
   PubMed Web of Science ®Google Scholar
• Coscas F, Glacet-Bernard A, Miere A, et al. Optical coherence tomography angiography in retinal vein occlusion: evaluation of superficial and deep capillary plexa. Am J Ophthalmol. 2016;161:160–171.
   PubMed Web of Science ®Google Scholar
• Argon laser photocoagulation for macular edema in branch vein occlusion. The branch vein occlusion study group. Am J Ophthalmol. 1984 15;98(3):271–282.
   PubMed Web of Science ®Google Scholar
• Quinlan PM, Elman MJ, Bhatt AK, et al. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990 Aug 15;110(2):118–123.
   PubMed Web of Science ®Google Scholar
• Natural history and clinical management of central retinal vein occlusion. The central vein occlusion study group. Arch Ophthalmol. 1997;115(4):486–491.
   PubMedGoogle Scholar
• Buehl W, Schmidt-Erfurth U. Treatment of branch retinal vein occlusion. Expert Rev Ophthalmol. 2009;4:661–669.
   Google Scholar
• Shuler RK Jr, Fekrat S. Does radial optic neurotomy alter retinal blood flow in eyes with a central retinal vein occlusion? Expert Rev Ophthalmol. 2006;1:77–82.
   Google Scholar
• Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol. 2006;90(5):627–639.
   PubMed Web of Science ®Google Scholar
• Parodi MB. Medical treatment of retinal vein occlusions. Semin Ophthalmol. 2004;19(1–2):43–48.
   PubMedGoogle Scholar
• La Spina C, De Benedetto U, Parodi MB, et al. Practical management of retinal vein occlusions. Ophthalmol Ther. 2012;1:3.
   PubMedGoogle Scholar
• Moisseiev E, Goldstein M, Waisbourd M, et al. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond). 2013;27(1):65–71.
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al.; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–2460.
   PubMed Web of Science ®Google Scholar
• Joshi L, Yaganti S, Gemenetzi M, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97(8):1040–1044.
   PubMed Web of Science ®Google Scholar
• Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644–1650.
   PubMedGoogle Scholar
• Varma R, Bressler NM, Suñer I, et al.; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119(10):2108–2118.
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al.; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–1133.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L, et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–1112.
   PubMed Web of Science ®Google Scholar
• Blodi BA, Domalpally A, Scott IU, et al.; SCORE Study Research Group. Standard care vs corticosteroid for retinal vein occlusion (SCORE) study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE study report 9. Arch Ophthalmol. 2010;128(9):1140–1145.
   PubMedGoogle Scholar
• Campochiaro PA, Sophie R, Pearlman J, et al.; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–219.
   PubMed Web of Science ®Google Scholar
• Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121:1414–1420.
   PubMed Web of Science ®Google Scholar
• Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024–1032.
   PubMed Web of Science ®Google Scholar
• Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2015;122:538–544.
   Google Scholar
• Isola V, Pece A, Massironi C, et al. Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients. Clin Ophthalmol. 2013;7:455–460.
   PubMedGoogle Scholar
• Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004;122(8):1131–1136.
   PubMedGoogle Scholar
• Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology. 2015;122:545–554.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Guymer R. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. Expert Rev Clin Pharmacol. 2015;8:541–548.
   PubMed Web of Science ®Google Scholar
• Li H, Lei N, Zhang M, et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res. 2012;97:154–159.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Narayanan R, Mathai A, et al. Short-term safety profile of intravitreal ziv aflibercept. Retina. 2015 Dec 11.
   Google Scholar
• Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014;98(Suppl 1):i11–i16.
   Web of Science ®Google Scholar
• Chen M, Li X, Liu J, et al. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015;10:109–117.
   Web of Science ®Google Scholar
• Miyamoto H, Ogura Y, Honda Y. [Hyperbaric oxygen treatment for macular edema after retinal vein occlusion–fluorescein angiographic findings and visual prognosis]. Nippon Ganka Gakkai Zasshi. 1995;99(2):220–225. Japanese.
   PubMedGoogle Scholar
• Knudtson MD, Klein BE, Klein R, et al. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005;123(6):807–814.
   PubMedGoogle Scholar